SEC Form SC 13G/A filed

2/8/21 10:29:25 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $NBIX alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No. 12 NEUROCRINE BIOSCIENCES INC COMMON STOCK Cusip #64125C109 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #64125C109 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 346,523 Item 6: 0 Item 7: 8,436,629 Item 8: 0 Item 9: 8,436,629 Item 11: 9.022% Item 12: HC Cusip #64125C109 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 8,436,629 Item 8: 0 Item 9: 8,436,629 Item 11: 9.022% Item 12: IN Item 1(a). Name of Issuer: NEUROCRINE BIOSCIENCES INC Item 1(b). Address of Issuer's Principal Executive Offices: 12780 EL CAMINO REAL San Diego, CA 92130 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 64125C109 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 8,436,629 (b) Percent of Class: 9.022% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 346,523 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 8,436,629 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of NEUROCRINE BIOSCIENCES INC. No one other person's interest in the COMMON STOCK of NEUROCRINE BIOSCIENCES INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 5, 2021 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC * IA Strategic Advisers LLC IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 5, 2021, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of NEUROCRINE BIOSCIENCES INC at December 31, 2020. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $NBIX alert in real time by email

Recent Analyst Ratings for

$NBIX

Date	Price Target	Rating	Analyst
6/2/2026	$213.00	Buy	Goldman
5/22/2026	$221.00	Outperform	Bernstein
2/24/2026	$160.00	Outperform	Wolfe Research
1/8/2026	$175.00	Overweight → Equal-Weight	Morgan Stanley
10/21/2025	$175.00	Buy	Citigroup
7/21/2025	$163.00	Buy	Truist
7/10/2025	$182.00	Buy	Goldman
4/15/2025	$138.00	Hold → Buy	Needham

More analyst ratings

SEC Form SC 13G/A filed

2/8/21 10:29:25 AM ET

$NBIX

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $NBIX alert in real time by email

Recent Analyst Ratings for

$NBIX

Date	Price Target	Rating	Analyst
6/2/2026	$213.00	Buy	Goldman
5/22/2026	$221.00	Outperform	Bernstein
2/24/2026	$160.00	Outperform	Wolfe Research
1/8/2026	$175.00	Overweight → Equal-Weight	Morgan Stanley
10/21/2025	$175.00	Buy	Citigroup
7/21/2025	$163.00	Buy	Truist
7/10/2025	$182.00	Buy	Goldman
4/15/2025	$138.00	Hold → Buy	Needham

More analyst ratings

SEC Form SC 13G/A filed

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NBIX

SEC Form SC 13G/A filed

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$NBIX

$NBIX
SEC Filings

Neurocrine Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

Neurocrine Biosciences Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 144 filed by Neurocrine Biosciences Inc.

$NBIX
Insider Trading

Chief Scientific Officer Onyia Jude exercised 11,000 shares at a strike of $84.74 and sold $1,762,710 worth of shares (11,000 units at $160.25) as part of a pre-agreed trading plan (SEC Form 4)

Chief Regulatory Officer Delaet Ingrid exercised 2,261 shares at a strike of $79.02 and sold $354,321 worth of shares (2,261 units at $156.71) as part of a pre-agreed trading plan (SEC Form 4)

Chief Scientific Officer Onyia Jude exercised 11,000 shares at a strike of $84.74 and sold $1,710,865 worth of shares (11,000 units at $155.53) as part of a pre-agreed trading plan (SEC Form 4)

$NBIX
Press Releases

Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

Neurocrine Biosciences to Present at Upcoming Investor Conferences in June

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

$NBIX
Analyst Ratings

Goldman resumed coverage on Neurocrine Biosciences with a new price target

Bernstein initiated coverage on Neurocrine Biosciences with a new price target

Wolfe Research initiated coverage on Neurocrine Biosciences with a new price target

$NBIX
FDA approvals

December 13, 2024 - FDA Approves New Treatment for Congenital Adrenal Hyperplasia

$NBIX
Leadership Updates

4basebio Announces Appointment of Chief Financial Officer and Board Changes

Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer

Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise

$NBIX
Financials

Neurocrine Biosciences Reports First-Quarter 2026 Financial Results

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results

Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

$NBIX
Large Ownership Changes

SEC Form SC 13G filed by Neurocrine Biosciences Inc.